N-Terminal domain antiandrogen

This is the current revision of this page, as edited by imported>JzG at 12:43, 11 January 2019 (rm. WP:REFSPAM). The present address (URL) is a permanent link to this version.

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.

N-Terminal domain antiandrogen
Drug class
EPI-001, the first major N-terminal domain AR antagonist to be developed.
Class identifiers
SynonymsN-Terminal domain AR antagonists; AR NTD antagonists
UseProstate cancer
Biological targetAndrogen receptor
Legal status

See also

References